B Cell Lymphoma
News
Rituximab boosts survival in primary CNS lymphoma
The triplet combination of rituximab plus combination high-dose methotrexate and temozolomide could be a safe and effective first-line option for...
News
High survival in relapsed FL after primary radiotherapy
The study supports the role of primary radiotherapy in the treatment of early-stage follicular lymphoma. But researchers found that patients who...
News
MCL survival rates improve with novel agents
Median overall survival for mantle cell patients was between 52 and 57 months in two cancer registries. The researchers pointed to the impact of...
News
Worse survival seen among black patients with MCL
There was a survival gap between black and white patients, even though black patients with mantle cell lymphoma were more likely to be treated in...
News
Venetoclax and obinutuzumab induces deep responses in CLL
The phase 1b, dose-escalation study is one of a few studies looking at the combination of venetoclax and obinutuzumab in chronic lymphocytic...
News
Short telomeres predict poorer response to chemo in CLL
High-throughput, single telomere–length analysis appears to be a useful tool in predicting response to FCR-based treatment among previously...
News
Bendamustine-rituximab shines in frontline treatment of MCL, iNHL
Long-term follow-up data from the BRIGHT study support bendamustine plus rituximab as a frontline treatment option in mantle cell lymphoma and...
News
Analysis suggests ‘Burkitt-like lymphoma’ is a misnomer
Burkitt-like lymphoma with 11q aberration appears more closely related to other lymphomas than to typical Burkitt lymphoma.
News
Gene expression signature reveals high-grade GCB DLBCL
Patients with this signature had inferior survival outcomes.
News
Priority review granted to lenalidomide for FL, MZL
Celgene is seeking approval for lenalidomide in combination with rituximab to treat previously treated follicular lymphoma or marginal zone...